kit for the preparation of technetium tc 99m-labeled carbon inhalation aerosol
TECHNEGAS KIT (kit for the preparation of technetium tc 99m-labeled carbon inhalation aerosol) by Cyclomedica is inhaled, they are mechanically deposited on the epithelium of ventilated pulmonary bronchioles and alveoli. First approved in 2023.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
TECHNEGAS KIT is a preparation kit for creating technetium Tc 99m-labeled carbon inhalation aerosol, used as a diagnostic imaging agent for pulmonary ventilation assessment. The product works through mechanical deposition of inhaled aerosol particles on the epithelium of ventilated bronchioles and alveoli, with distribution determined by lung aerodynamic function rather than receptor-mediated mechanisms. This is a diagnostic radiopharmaceutical indicated for lung ventilation imaging.
Early-stage product in growth phase post-approval with minimal current linked commercial roles, suggesting opportunity to build market presence and expand team infrastructure.
inhaled, they are mechanically deposited on the epithelium of ventilated pulmonary bronchioles and alveoli. Localization of the aerosol is not mediated by specific pharmacologic receptors; rather the distribution is determined by the aerodynamic function of the lungs.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
LOE in ~5 years — strategic planning for patent cliff underway
Worked on TECHNEGAS KIT at Cyclomedica? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TECHNEGAS offers early-stage career opportunity in a recently approved diagnostic product with 4.6 years of patent protection and growth trajectory. The minimal current job market presence suggests opportunity to build foundational commercial infrastructure and establish yourself as category expert in a specialized nuclear medicine niche.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo